Durvalumab in combination with carboplatin and paclitaxel is indicated for the first-line treatment of adults with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy
The British-Swedish pharma major certainly has a strong competitive edge for BTC treatment in the country
Durvalumab in combination with chemotherapy is indicated for the treatment of patients with locally advanced or metastatic biliary tract cancer
First immunotherapy combination approved in the US for BCG-naïve high-risk NMIBC demonstrates a 32% reduction in the risk of disease recurrence, progression, or death
The safety profile was described as manageable, though not without notable toxicities
While overall survival data remain immature, the results pointed to a favourable trend.
The study tracked patients for more than five years (median 60.7 months), with protection against disease returning emerging in under four months and continuing long term
Across more than 85 abstracts, AstraZeneca will showcase 10 approved medicines and 13 potential new therapies
The study has shown that perioperative treatment with Imfinzi (durvalumab), alone or in combination with other immunotherapy agents
The study met its primary endpoint, showing a statistically significant and clinically meaningful improvement in progression-free survival
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
